Researchers and people living with hepatitis B meet in Paris at the third Hepatitis B Community Forum <<Click here>>

News Archive

News Archive

New Guidelines Clarify Use of Systemic Therapy in Advanced HCC

ASTRO Issues Clinical Guideline on External Beam Radiation Therapy for Primary Liver Cancers

After FDA Evaluation, BMS Withdraws Opdivo For Liver Cancer Treatment in Patients Previously Treated with Sorafenib in the U.S.

FDA Grants “Orphan Drug” Designation to Chemotherapeutic Uttroside-B for Use in Patients with HCC. The drug is in pre-clinical testing.

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline

COVID-19: What People With Cancer Need to Know (Cancer.net, June 2020)

FDA Approves Atezolizumab Plus Bevacizumab for Patients With Unresectable or Metastatic Hepatocellular Carcinoma 

Atezolizumab Combination Improves Survival in HCC (Cancer Letter, May 2020)

U.S. FDA Approves Opdivo® (Nivolumab) + Yervoy® (Ipilimumab) for Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib

U.S. Food and Drug Administration (FDA) Has Granted Breakthrough Device Designation to the Elecsys® GALAD Score to Help Diagnose HCC

FDA Has Approved Cabozantinib (CABOMETYX, Exelixis, Inc.) for Patients with Hepatocellular Carcinoma Who Have Been Previously Treated with Sorafenib

DNA Search Finds People Resistant to Liver Disease. Can We Mimic This Effect with a Drug? Regeneron and Alnylam Pharmaceutical to Partner  

Newly Discovered Anti-Cancer Protein LHPP Prevents Uncontrolled Proliferation of Cancer Cells in the Liver and May Serve as a Biomarker for the Diagnosis & Prognosis of Liver Cancer